Adaptive Designs in Clinical Drug Development (2012)

What is this event about?

Join us for our 6th anuual event, the only Adaptive Designs in Clinical Drug Development conference in the UK!

In recent years, the use of adaptive design in clinical trials has been considered an efficient and optimal way of designing clinical trials.

Adaptive design has gradually evolved from a novel idea into a standard norm in the pharmaceutical industry. This new clinical paradigm could change the way traditional clinical trials, with their restrictive guidance, are run today.

With more flexibility, faster development timelines and significant monetary savings, an adaptive design trial is the way forward.

SMi’s 6th annual Adaptive Designs in Clinical Drug Development conference will shine a spotlight on the industry in this rapidly advancing novel technique.
 

 Why should you attend this event?

Learn from the industry's leading pioneers and take back new approaches to your work!

Key Areas Covered:   Case studies from leading pharmaceutical companies on their use of adaptive clinical trials   Maximising the benefits of an adaptive design through effective management   Adaptive design within a Bayesian framwework   Tried and tested - case studies of successful adaptive design trials  'Out with the old, in with the new' - to adapt or not to adapt?

Speakers from this year's event includes:  • Graeme Archer, Director, Quantitative Sciences – Clinical Statistics, GlaxoSmithKline • Robert Clay, Vice President Regulatory Affairs, Oncology and Infection, AstraZeneca Sandrine Micallef, Clinical Biostatistics Oncology, Sanofi-Aventis • Giacomo Mordenti, Senior Expert Biostatistician, Merck Serono • Barbara Bogacka, Reader in Statistics, Queen Mary, University of London • Markus Niggli, Project Statistician & Annette Sauter, Project Statistician, Roche • Prof Christopher Jennison, Professor of Statistics, University of Bath • Frank Fleischer, Teamleader Clinical Biostatistics, Boehringer Ingelheim • Pantelis Vlachos, Principal Specialist, Merck • Edwin Wagena, Vice President, Clinical Development, Kiadis Pharma • Les Huson, Honorary Lecturer in Medical Statistics, Imperial College London • Yongming Qu, Research Advisor, Eli Lilly • Yu Shyr, Professor, Cancer Biostatistics, Vanderbilt University • Patrick Johnson, Head Global Biometrics, Vifor Pharma • Eric Silva, Cytel • Vera Lisovskaja, Department of Mathematical Sciences, Chalmers University of Technology and Göteborg University Professor Andy Grieve, Senior Vice President Clinical Trial Methodology, Aptiv Solutions

Who should attend this event?

Chief Executives, Vice Presidents, Executive Directors, Heads, Senior Scientists, Team Leaders of:   Biostatistics Adaptive Trials Trial Design Drug Development Clinical Trials Regulatory Affairs Drug & Safety Assessment Data Management Drug Supply Logistics Clinical Research Clinical Statistics Contract Research   Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know - contact the Conference Producer. For sponsorship and exhibiting opportunities,contact our Sponsorship Department

Participants from Other Conferences in this Series Have Come from Organizations Including: 

Abbott Laboratories Amgen AstraZeneca Bayer  Boehringer Ingelheim  Bristol-Myers Squibb  Celgene Cephalon Cytel Eli Lilly  FDA Genentech Genzyme GlaxosmithKline Grunenthal Gmbh  Johnson & Johnson Merck & Co Novartis Novo Nordisk Orion Pharma Pfizer  Queen Mary University London Roche  Sanofi-Aventis Shire  Tessella Wyeth